BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis
Momentum Cont setup
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $55.88: Concentration risk — Customer: top-3 customers (37.0%); Concentration risk — Customer: Sanofi.
BioMarin Pharmaceutical develops and commercializes rare disease medicines with 8 commercial products including VOXZOGO ($926.9M) for achondroplasia, VIMIZIM ($792.1M) for MPS IVA, and NAGLAZYME ($485.4M) for MPS VI, totaling $3.2B in 2025 revenues. Products target genetically... Read more
Sell if holding. Multiple concerning factors at $55.88: Concentration risk — Customer: top-3 customers (37.0%); Concentration risk — Customer: Sanofi. Chart setup: Trend continuation, RSI 55, MACD bullish. Score 5.2/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent developments
updated 2026-06-13Recent Developments — BioMarin Pharmaceutical Inc.
Latest news
- NEWS BioMarin Pharmaceutical (BMRN) Projected to Post Quarterly Earnings on Monday - MarketBeat — MarketBeat neutral
- NEWS Earnings Preview: BMRN to Report Financial Results Post-market on May 04 - Moomoo — Moomoo neutral
- NEWS Cwm LLC Sells 77,791 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat — MarketBeat negative
- NEWS BIOMARIN PHARMACEUTICAL INC ($BMRN) President, CEO 2025 Pay Revealed - Quiver Quantitative — Quiver Quantitative positive
- NEWS Zurcher Kantonalbank Zurich Cantonalbank Sells 99,451 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat — MarketBeat neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomertop-3 customers37%10-K Item 1: 'During 2025, 37% of our net product revenue was generated by three customers'
- HIGHCustomerSanofi10-K Item 1: 'Sanofi is our sole customer for ALDURAZYME and is responsible for distributing, marketing, and selling ALDURAZYME to third parties'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $55.88: Concentration risk — Customer: top-3 customers (37.0%); Concentration risk — Customer: Sanofi. Chart setup: Trend continuation, RSI 55, MACD bullish. Prior stop was $52.31. Score 5.2/10, moderate confidence.
Take-profit target: $79.06 (+41.3% upside). Prior stop was $52.31. Stop-loss: $52.31.
Concentration risk — Customer: top-3 customers (37.0%); Concentration risk — Customer: Sanofi; Consecutive earnings misses (3).
BioMarin Pharmaceutical Inc. trades at a P/E of 40.0 (forward 8.6). TrendMatrix value score: 7.3/10. Verdict: Sell.
34 analysts cover BMRN with a consensus score of 4.1/5. Average price target: $88.
What does BioMarin Pharmaceutical Inc. do?BioMarin Pharmaceutical develops and commercializes rare disease medicines with 8 commercial products including VOXZOGO...
BioMarin Pharmaceutical develops and commercializes rare disease medicines with 8 commercial products including VOXZOGO ($926.9M) for achondroplasia, VIMIZIM ($792.1M) for MPS IVA, and NAGLAZYME ($485.4M) for MPS VI, totaling $3.2B in 2025 revenues. Products target genetically defined small patient populations requiring high per-patient pricing with global commercialization. A pending $4.8B acquisition of Amicus Therapeutics is expected to close in Q2 2026.